Topical Dorzolamide for Idiopathic Macular Hole

A randomised clinical trial, to evaluate the efficacy of topical dorzolamide for the treatment of idiopathic macular hole

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12619000660189

Enrollment

Registered

2019-05-02

Start date

2020-02-28

Completion date

Unknown

Last updated

2021-09-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

This randomised controlled trial will assess the efficacy of topical dorzolamide achieving macular hole closure prior to vitreoretinal surgery.

Interventions

In this double blinded study, those randomised to treatment will receive 2% dorzolamide drops to the eye three times per day for 8 weeks. Drops will be self administered by the patient following detailed instruction and will not be supervised.

Study design

Allocation

Randomised controlled trial

Intervention model

Parallel

Primary purpose

Treatment

Masking

Blinded (masking used) (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Ability to provide informed consent and complete study assessments Age 18 years or older Idiopathic macular hole in study eye

Exclusion criteria

Renal impairment with creatinine clearance <30ml/min. Other retinal pathology

Outcome results